Search

Your search keyword '"Dosquet, Christine"' showing total 41 results
Start Over Author "Dosquet, Christine" Publication Year Range Last 10 years
41 results on '"Dosquet, Christine"'

4. Note d'étape sur le Health Data Hub, les entrepôts de données de santé et les questions éthiques posées par la collecte et le traitement de données desanté dites « massives »

Author

Lombrail, Pierre, Nisand, Israël, Dosquet, Christine, Lesaulnier, Frédérique, Bourgain, Catherine, Baertschi, Bernard, Buisson, Anne, Cornu, Catherine, Hirsch, François, Lemaitre, Christine, Ledoux, Sylvie, Mathieu, Flavie, Rémy-Jouet, Isabelle, Sadani, Yamina, Duchange, Nathalie, Comité d'éthique de l'Inserm (CEI), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13), Université de Strasbourg (UNISTRA), AP -Comité d'évaluation éthique de l'Inserm, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université de Genève = University of Geneva (UNIGE), Association François Aupetit, Inserm - Ethique des sciences de la vie, éthique de la recherche dans les pays du Sud, Inserm - Institut Biologie cellulaire, développement et évolution, Inserm - Service Sciences et société, and Inserm - Assurance qualité, technologies pour la santé

Subjects
Note Comité Ethique Inserm, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note du Comité Ethique, Groupe HDH-DSM; Le CEI a mis en place un groupe de travail en octobre 2020 du fait des interrogations soulevées par la décision de confier l’hébergement des données du Système national des Données de Santé (SNDS) rassemblées par le Health Data Hub (HDH ou PDS pour Plateforme des données de santé) à la société Microsoft à travers son « cloud » Azure. Le groupe a été amené rapidement à élargir sa réflexion à un ensemble plus vaste de questions éthiques soulevées par la collecte et le traitement de données dites « massives » pouvant s’apparenter de près ou de loin à des données de santé.

Published
2022

5. Interim Memo on the Health Data Hub, health data warehouses, and the ethical questions raised by the collection and processing of Health Big Data

Author

Lombrail, Pierre, Nisand, Israël, Dosquet, Christine, Lesaulnier, Frédérique, Bourgain, Catherine, Baertschi, Bernard, Buisson, Anne, Cornu, Catherine, Hirsch, François, Lemaitre, Christine, Ledoux, Sylvie, Mathieu, Flavie, Rémy-Jouet, Isabelle, Sadani, Yamina, Duchange, Nathalie, The Inserm Ethics Committee (IEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris 13 (UP13), Université de Strasbourg (UNISTRA), AP -Comité d'évaluation éthique de l'Inserm, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université de Genève = University of Geneva (UNIGE), Association François Aupetit, Inserm - Ethique des sciences de la vie, éthique de la recherche dans les pays du Sud, Inserm - Institut Biologie cellulaire, développement et évolution, Inserm - Service Sciences et société, and Inserm - Assurance qualité, technologies pour la santé

Subjects
Note Inserm Ethics Committee, Note Comité Ethique Inserm, IEC, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note from the Ethics Committee, "HDH/HBD" Working group; In October 2020, the Inserm Ethics Committee (CEI) set up a Working Group in response to the questions raised by the decision to entrust the hosting of French National Health Data System (SNDS) data gathered by the Health Data Hub (HDH) to Microsoft through its cloud computing platform Azure. However, the group very quickly had to expand its reflection to include a much broader set of ethical questions raised by the collection and processing of Big Data relating to health data however remotely.

Published
2022

6. Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms

Author

Marcault, Clémence, Zhao, Lin-Pierre, Maslah, Nabih, Verger, Emmanuelle, Daltro de Oliveira, Rafael, Soret-Dulphy, Juliette, Cazaux, Marine, Gauthier, Nicolas, Roux, Blandine, Clappier, Emmanuelle, Parquet, Nathalie, Dosquet, Christine, Réa, Delphine, Zini, Jean-Marc, Vainchenker, William, Raffoux, Emmanuel, Giraudier, Stéphane, Kiladjian, Jean-Jacques, Cassinat, Bruno, and Benajiba, Lina

Published
2021
Full Text
View/download PDF

7. Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

Author

Zhao, Lin-Pierre, primary, Maslah, Nabih, additional, Daltro De Oliveira, Rafael, additional, Verger, Emmanuelle, additional, Soret-Dulphy, Juliette, additional, Marcault, Clemence, additional, Parquet, Nathalie, additional, Dosquet, Christine, additional, Vainchenker, William, additional, Raffoux, Emmanuel, additional, Giraudier, Stephane, additional, Kiladjian, Jean-Jacques, additional, Cassinat, Bruno, additional, Benajiba, Lina, additional, and Cazaux, Marine, additional

Published
2021
Full Text
View/download PDF

8. Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

Author

Zhao, Lin-Pierre, primary, Cazaux, Marine, additional, Maslah, Nabih, additional, Daltro De Oliveira, Rafael, additional, Verger, Emmanuelle, additional, Soret-Dulphy, Juliette, additional, Marcault, Clemence, additional, Parquet, Nathalie, additional, Dosquet, Christine, additional, Vainchenker, William, additional, Raffoux, Emmanuel, additional, Giraudier, Stephane, additional, Kiladjian, Jean-Jacques, additional, Cassinat, Bruno, additional, and Benajiba, Lina, additional

Published
2021
Full Text
View/download PDF

9. Evaluation of PReimplantation embryo Aptitude for DEvelopment (EPRADE)

Author

Baertschi, Bernard, Bed’hom, Bertrand, Dosquet, Christine, Grosset, Marie, Dubart-Kupperschmitt, Anne, Jouannet, Pierre, Lemaitre, Christine, Moutel, Grégoire, Nisand, Israël, Remy-Jouet, Isabelle, Duchange, Nathalie, Comité d'éthique de l'Inserm (CEI), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), Muséum national d'Histoire naturelle (MNHN), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), AP -Comité d'évaluation éthique de l'Inserm, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Fertilité et reproduction humaines- Université Paris 5, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Espace régional de réflexion éthique de Normandie (EREN), Biologie de la reproduction, Université de Strasbourg (UNISTRA), and Inserm - Assurance qualité, technologies pour la santé

Subjects
Note Inserm Ethics Committee, Note Comité Ethique Inserm, IEC, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Memo by the Inserm Ethics Committee. Embryo and Developmental Group. Written by: Bernard Baertschi and Pierre Jouannet

Published
2021

10. L’évaluation préimplantatoire de l’aptitude au développement embryonnaire (EPRADE)

Author

Baertschi, Bernard, Bed’hom, Bertrand, Dosquet, Christine, Grosset, Marie, Dubart-Kupperschmitt, Anne, Jouannet, Pierre, Lemaitre, Christine, Moutel, Grégoire, Nisand, Israël, Rémy-Jouet, Isabelle, Duchange, Nathalie, Comité d'éthique de l'Inserm (CEI), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), Muséum national d'Histoire naturelle (MNHN), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), AP -Comité d'évaluation éthique de l'Inserm, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Fertilité et reproduction humaines- Université Paris 5, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Espace régional de réflexion éthique de Normandie (EREN), Biologie de la reproduction, Université de Strasbourg (UNISTRA), and Inserm - Assurance qualité, technologies pour la santé

Subjects
DPI, Procréation médicalement assistée, Comité Ethique Inserm, Diagnostic préimplantatoire, Assistance médicale à la procréation, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, Embryon, FIV, PMA, AMP, Fécondation in vitro, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note du groupe « Embryon et développement » du Comité d'Éthique de l'INSERM. Rédaction: Bernard Baertschi et Pierre Jouannet

Published
2021

11. Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms

Author

Faille, Dorothée, Lamrani, Lamia, Loyau, Stéphane, Huisse, Marie-Geneviève, Bourrienne, Marie-Charlotte, Alkhaier, Sawsaneh, Cassinat, Bruno, Boulaftali, Yacine, Debus, Jérôme, Jandrot-Perrus, Martine, Chomienne, Christine, Dosquet, Christine, and Ajzenberg, Nadine

Subjects
hemic and lymphatic diseases, prothrombotic markers, interferon, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Article, myeloproliferative neoplasms
Abstract

Myeloproliferative neoplasms (MPN) are associated with an increased risk of arterial and venous thrombosis. Pegylated-interferon alpha (IFN) and hydroxyurea (HU) are commonly used to treat MPN, but their effect on hemostasis has not yet been studied. The aim of our study was to determine whether IFN and HU impact the biological hemostatic profile of MPN patients by studying markers of endothelial, platelet, and coagulation activation. A total of 85 patients (50 polycythemia vera and 35 essential thrombocythemia) were included: 28 treated with IFN, 35 with HU, and 22 with no cytoreductive drug (non-treated, NT). Von Willebrand factor, shear-induced platelet aggregation, factor VIII coagulant activity (FVIII:C), fibrinogen, and thrombin generation with and without exogenous thrombomodulin were significantly higher in IFN-treated patients compared to NT patients, while protein S anticoagulant activity was lower. In 10 patients in whom IFN therapy was discontinued, these hemostatic biomarkers returned to the values observed in NT patients, strongly suggesting an impact of IFN therapy on endothelial and coagulation activation. Overall, our study shows that treatment with IFN is associated with significant and reversible effects on the biological hemostatic profile of MPN patients. Whether they could be associated with an increased thrombotic risk remains to be determined in further randomized clinical studies.

Published
2020

12. Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements

Author

Drevon, Louis, primary, Maslah, Nabih, additional, Soret-Dulphy, Juliette, additional, Dosquet, Christine, additional, Ravdan, Odno, additional, Vercellino, Laetitia, additional, Belkhodja, Celia, additional, Parquet, Nathalie, additional, Brignier, Anne C., additional, Schlageter, Marie-Helene, additional, Cassinat, Bruno, additional, Kiladjian, Jean-Jacques, additional, Chomienne, Christine, additional, and Giraudier, Stéphane, additional

Published
2021
Full Text
View/download PDF

13. SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Author

Zhao, Lin-Pierre, primary, Daltro De Oliveira, Rafael, additional, Marcault, Clemence, additional, Soret, Juliette, additional, Gauthier, Nicolas, additional, Verger, Emmanuelle, additional, Maslah, Nabih, additional, Roux, Blandine, additional, Parquet, Nathalie, additional, Dosquet, Christine, additional, Rea, Delphine, additional, Zini, Jean-Marc, additional, Vainchenker, William, additional, Raffoux, Emmanuel, additional, Giraudier, Stephane, additional, Cassinat, Bruno, additional, Kiladjian, Jean-Jacques, additional, and Benajiba, Lina, additional

Published
2020
Full Text
View/download PDF

14. NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN)

Author

Marcault, Clemence, primary, Zhao, Lin-Pierre, additional, Daltro De Oliveira, Rafael, additional, Soret, Juliette, additional, Gauthier, Nicolas, additional, Verger, Emmanuelle, additional, Maslah, Nabih, additional, Roux, Blandine, additional, Parquet, Nathalie, additional, Dosquet, Christine, additional, Rea, Delphine, additional, Zini, Jean-Marc, additional, Vainchenker, William, additional, Raffoux, Emmanuel, additional, Giraudier, Stephane, additional, Cassinat, Bruno, additional, Kiladjian, Jean-Jacques, additional, and Benajiba, Lina, additional

Published
2020
Full Text
View/download PDF

16. Organoids Research: What are the ethical issues?

Author

Baertschi, Bernard, Atlan, Henri, Botbol-Baum, Mylène, Bed’hom, Bertrand, Combrisson, Hélène, Dosquet, Christine, Dubart-Kupperschmitt, Anne, Hirsch, François, Jouannet, Pierre, Remy-Jouet, Isabelle, Lemaitre, Christine, Moutel, Grégoire, Duchange, Nathalie, The Inserm Ethics Committee (IEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), École des hautes études en sciences sociales (EHESS), Université Catholique de Louvain = Catholic University of Louvain (UCL), Muséum national d'Histoire naturelle (MNHN), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), École nationale vétérinaire - Alfort (ENVA), AP -Comité d'évaluation éthique de l'Inserm, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Inserm - Ethique des sciences de la vie, éthique de la recherche dans les pays du Sud, Fertilité et reproduction humaines- Université Paris 5, Inserm - Assurance qualité, technologies pour la santé, Inserm - Institut Biologie cellulaire, développement et évolution, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Espace régional de réflexion éthique de Normandie (EREN)

Subjects
Note Inserm Ethics Committee, Note Comité Ethique Inserm, IEC, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note from the Ethics committee.

Published
2020

17. La recherche sur les organoïdes: quels enjeux éthiques?

Author

Baertschi, Bernard, Atlan, Henri, Botbol-Baum, Mylène, Bed’hom, Bertrand, Combrisson, Hélène, Dosquet, Christine, Dubart-Kupperschmitt, Anne, Hirsch, François, Jouannet, Pierre, Remy-Jouet, Isabelle, Lemaitre, Christine, Moutel, Grégoire, Duchange, Nathalie, Comité d'éthique de l'Inserm (CEI), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), École des hautes études en sciences sociales (EHESS), Université Catholique de Louvain = Catholic University of Louvain (UCL), Muséum national d'Histoire naturelle (MNHN), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), École nationale vétérinaire - Alfort (ENVA), AP -Comité d'évaluation éthique de l'Inserm, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Inserm - Ethique des sciences de la vie, éthique de la recherche dans les pays du Sud, Fertilité et reproduction humaines- Université Paris 5, Inserm - Assurance qualité, technologies pour la santé, Inserm - Institut Biologie cellulaire, développement et évolution, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Espace régional de réflexion éthique de Normandie (EREN)

Subjects
Note Comité Ethique Inserm, iPS, MEUS, cellules souches, organe, CEI, organoïdes, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note du Comité. Groupe "Recherche sur les organoïdes"

Published
2020

18. Research on Embryos and Embryonic Models for Scientific Use (EMSUs)

Author

Baertschi, Bernard, Brodin, Marc, Dosquet, Christine, Jouannet, Pierre, Lapointe, Anne-Sophie, Merchant, Jennifer, Moutel, Grégoire, Duchange, Nathalie, The Inserm Ethics Committee (IEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), AP -Comité d'évaluation éthique de l'Inserm, Université Paris Descartes - Paris 5 (UPD5), Ministère de la santé, Université Panthéon-Assas (UP2), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Espace régional de réflexion éthique de Normandie (EREN)

Subjects
animal structures, Note Inserm Ethics Committee, Note Comité Ethique Inserm, embryonic structures, education, IEC, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note from the Ethics Committee 'Embryo and Developemental" Group

Published
2019

20. Autologous 111 Indium‐oxinate‐labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor‐agonists

Author

Mahevas, Matthieu, primary, Van Eeckhoudt, Sandrine, additional, Moulis, Guillaume, additional, Limal, Nicolas, additional, Languille, Laetitia, additional, Bierling, Philippe, additional, Dossier, Antoine, additional, Duriez, Frédéric, additional, Galicier, Lionel, additional, Morin, Anne‐Sophie, additional, Tamburini, Jérôme, additional, Chaoui, Driss, additional, Bouscary, Didier, additional, Jijakli, Ahmad A. L., additional, Khellaf, Mehdi, additional, Vaida, Ioana, additional, Michel, Marc, additional, Vercellino, Laetitia, additional, Jaddi, Hind, additional, Yollant, Armelle, additional, Dosquet, Christine, additional, Godeau, Bertrand, additional, and Chomienne, Christine, additional

Published
2019
Full Text
View/download PDF

22. De la recherche à la thérapie embryonnaire

Author

Baertschi, Bernard, Brodin, Marc, Dosquet, Christine, Jouannet, Pierre, Lapointe, Anne-Sophie, Merchant, Jennifer, Moutel, Grégoire, Duchange, Nathalie, Comité d'éthique de l'Inserm (CEI), Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), AP -Comité d'évaluation éthique de l'Inserm, Université Paris 2 - Enjeux bioéthiques des politiques publiques comparées, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Espace régional de réflexion éthique de Normandie (EREN)

Subjects
Note Comité Ethique Inserm, embryon, approches thérapeutiques, [SDV.BDD] Life Sciences [q-bio]/Development Biology, CEI, recherche, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.BDD]Life Sciences [q-bio]/Development Biology, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Notes du Comité; Travaux du groupe "Embryon et Développement"

Published
2017

23. From Embryo Research to Therapy

Author

Baertschi, Bernard, Brodin, Marc, Dosquet, Christine, Jouannet, Pierre, Lapointe, Anne-Sophie, Merchant, Jennifer, Moutel, Grégoire, Duchange, Nathalie, The Inserm Ethics Committee (IEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Genève = University of Geneva (UNIGE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), AP -Comité d'évaluation éthique de l'Inserm, Université Paris Descartes - Paris 5 (UPD5), Ministère des Solidarités et de la Santé [Paris, France], Université Panthéon-Assas (UP2), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Espace régional de réflexion éthique de Normandie (EREN)

Subjects
therapy, animal structures, Note Inserm Ethics Committee, Note Comité Ethique Inserm, embryonic structures, education, embryo, IEC, CEI, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics
Abstract

Note from the Inserm Ethics Committee. "Embryo and Developmental Research" group

Published
2017

26. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Author

Ianotto, Jean-Christophe, primary, Chauveau, Aurélie, additional, Boyer-Perrard, Françoise, additional, Gyan, Emmanuel, additional, Laribi, Kamel, additional, Cony-Makhoul, Pascale, additional, Demory, Jean-Loup, additional, de Renzis, Benoit, additional, Dosquet, Christine, additional, Rey, Jerome, additional, Roy, Lydia, additional, Dupriez, Brigitte, additional, Knoops, Laurent, additional, Legros, Laurence, additional, Malou, Mohamed, additional, Hutin, Pascal, additional, Ranta, Dana, additional, Benbrahim, Omar, additional, Ugo, Valérie, additional, Lippert, Eric, additional, and Kiladjian, Jean-Jacques, additional

Published
2017
Full Text
View/download PDF

28. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET

Author

Vercellino, Laetitia, primary, Ouvrier, Matthieu John, additional, Barré, Emmanuelle, additional, Cassinat, Bruno, additional, de Beco, Virginie, additional, Dosquet, Christine, additional, Chevret, Sylvie, additional, Meignin, Véronique, additional, Chomienne, Christine, additional, Toubert, Marie-Elisabeth, additional, Merlet, Pascal, additional, and Kiladjian, Jean-Jacques, additional

Published
2017
Full Text
View/download PDF

29. Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Author

Mahevas, Matthieu, primary, Van Eeckhoudt, Sandrine, additional, Moulis, Guillaume, additional, Dosquet, Christine, additional, Michel, Marc, additional, Limal, Nicolas, additional, Languille, Laetitia, additional, Alkaeir, Sawsaneh, additional, Bierling, Philippe, additional, Dossier, Antoine, additional, Duriez, Frédéric, additional, Galicier, Lionel, additional, Morin, Anne-Sophie, additional, Tamburini, Jérôme, additional, Chaoui, Driss, additional, Bouscary, Didier, additional, AL Jijakli, Ahmad, additional, Khellaf, Mehdi, additional, Vaida, Ioana, additional, Godeau, Bertrand, additional, and Chomienne, Christine, additional

Published
2016
Full Text
View/download PDF

30. Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms

Author

Ajzenberg, Nadine, primary, Faille, Dorothee, additional, Lamrani, Lamia, additional, Loyau, Stéphane, additional, Huisse, Marie-Geneviève, additional, Dumontier, Nicolas, additional, Jandrot-Perrus, Martine, additional, Alkhaier, Sawsaneh, additional, Cassinat, Bruno, additional, Chomienne, Christine, additional, and Dosquet, Christine, additional

Published
2016
Full Text
View/download PDF

32. Hind limb unloading, a model of spaceflight conditions, leads to decreased B lymphopoiesis similar to aging

Author

Lescale, Chloé, Schenten, Véronique, Djeghloul, Dounia, Bennabi, Meriem, Gaignier, Fanny, Vandamme, Katleen, Strazielle, Catherine, Kuzniak, Isabelle, Petite, Hervé, Dosquet, Christine, Frippiat, Jean-Pol, Goodhardt, Michèle, Lescale, Chloé, Schenten, Véronique, Djeghloul, Dounia, Bennabi, Meriem, Gaignier, Fanny, Vandamme, Katleen, Strazielle, Catherine, Kuzniak, Isabelle, Petite, Hervé, Dosquet, Christine, Frippiat, Jean-Pol, and Goodhardt, Michèle

Abstract

Within the bone marrow, the endosteal niche plays a crucial role in B-cell differentiation. Because spaceflight is associated with osteoporosis, we investigated whether changes in bone microstructure induced by a ground-based model of spaceflight, hind limb unloading (HU), could affect B lymphopoiesis. To this end, we analyzed both bone parameters and the frequency of early hematopoietic precursors and cells of the B lineage after 3, 6, 13, and 21 d of HU. We found that limb disuse leads to a decrease in both bone microstructure and the frequency of B-cell progenitors in the bone marrow. Although multipotent hematopoietic progenitors were not affected by HU, a decrease in B lymphopoiesis was observed as of the common lymphoid progenitor (CLP) stage with a major block at the progenitor B (pro-B) to precursor B (pre-B) cell transition (5- to 10-fold decrease). The modifications in B lymphopoiesis were similar to those observed in aged mice and, as with aging, decreased B-cell generation in HU mice was associated with reduced expression of B-cell transcription factors, early B-cell factor (EBF) and Pax5, and an alteration in STAT5-mediated IL-7 signaling. These findings demonstrate that mechanical unloading of hind limbs results in a decrease in early B-cell differentiation resembling age-related modifications in B lymphopoiesis.

Published
2015

33. Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Author

Ianotto, Jean-Christophe, Chauveau, Aurélie, Boyer-Perrard, Francoise, Gyan, Emmanuel, Laribi, Kamel, Cony-Makhoul, Pascale, Demory, Jean-Loup, De Renzis, Benoit, Dosquet, Christine, Rey, Jerome, Roy, Lydia, Dupriez, Brigitte, Knoops, Laurent, Legros, Laurence, Malou, Mohamed, Hutin, Pascal, Ranta, Dana, Benbrahim, Omar, Ugo, Valerie, Lippert, Eric, and Kiladjian, Jean-Jacques

Published
2017
Full Text
View/download PDF

35. SF3B1mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

Author

Zhao, Lin-Pierre, Daltro De Oliveira, Rafael, Marcault, Clemence, Soret, Juliette, Gauthier, Nicolas, Verger, Emmanuelle, Maslah, Nabih, Roux, Blandine, Parquet, Nathalie, Dosquet, Christine, Rea, Delphine, Zini, Jean-Marc, Vainchenker, William, Raffoux, Emmanuel, Giraudier, Stephane, Cassinat, Bruno, Kiladjian, Jean-Jacques, and Benajiba, Lina

Abstract

Introduction:

Published
2020
Full Text
View/download PDF

38. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Author

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, and Kiladjian JJ

Subjects
Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myeloproliferative Disorders genetics, Myeloproliferative Disorders mortality, Primary Myelofibrosis genetics, Primary Myelofibrosis mortality, Prognosis, Recombinant Proteins therapeutic use, Risk Assessment, Survival Analysis, Interferon-alpha therapeutic use, Myeloproliferative Disorders drug therapy, Polyethylene Glycols therapeutic use, Primary Myelofibrosis drug therapy
Abstract

We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyzed by targeted next generation sequencing. The median age at diagnosis was 66 years old, the median follow-up since starting pegylated interferon was 58 months. At the time of analysis, 30 (48.4%) patients were alive including 16 still being treated with pegylated interferon. The median survival of patients with intermediate and high-risk prognostic Lille and dynamic International Prognostic Scoring System scores treated with pegylated interferon was increased in comparison to that of historical cohorts. In addition, overall survival was significantly correlated with the duration of pegylated interferon therapy (70 versus 30 months after 2 years of treatment, P <10 -12 ). JAK2 V617F allele burden was decreased by more than 50% in 58.8% of patients and two patients even achieved complete molecular response. Next-generation sequencing analyses performed in 49 patients showed that 28 (57.1%) of them carried non-driver mutations. The presence of at least one additional mutation was associated with a reduction of both overall and leukemia-free survival. These findings in a large series of patients with myelofibrosis suggest that pegylated interferon therapy may provide a survival benefit for patients with intermediate- or high-risk Lille and dynamic International Prognostic Scoring System scores. It also reduced the JAK2 V617F allele burden in most patients. These results further support the use of pegylated interferon in selected patients with myelofibrosis., (Copyright© 2018 Ferrata Storti Foundation.)

Published
2018
Full Text
View/download PDF

39. [Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes].

Author

Goulard M, Dosquet C, and Chomienne C

Subjects
Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Mutation, Myelodysplastic Syndromes genetics, Precision Medicine methods, Tumor Suppressor Protein p53 genetics, Young Adult, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes therapy, Transplantation Conditioning methods
Published
2018
Full Text
View/download PDF

40. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18 F-FLT PET.

Author

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, and Kiladjian JJ

Subjects
Aged, Bone Marrow pathology, Female, Humans, Male, Middle Aged, Pilot Projects, Primary Myelofibrosis pathology, Prognosis, Bone Marrow diagnostic imaging, Dideoxynucleosides, Positron-Emission Tomography, Primary Myelofibrosis diagnostic imaging
Abstract

An emerging noninvasive approach to assess tissue proliferation uses the PET tracer 3'-deoxy-3'- 18 F-fluorothymidine ( 18 F-FLT). To evaluate the diagnostic value of this technique in myelofibrosis, 18 F-FLT PET imaging results were compared with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this clinical situation. Methods: Fifteen patients with histology-proven myelofibrosis were included consecutively in the study. Tracers' distributions were assessed using a visual grading assessment score of the uptake in the axial skeleton, proximal and distal limbs, liver, and spleen. This visual score was used to define patterns of tracer distribution and to compare the information provided either by PET or by BMS. A semiquantitative analysis with determination of SUV max in the same localizations was performed for 18 F-FLT PET. Results: The histology grade of fibrosis correlated with the SUV max in the axial skeleton (spine and iliac crests) and proximal limbs. 18 F-FLT uptake in these areas was much lower in patients with grade 3 fibrosis than in patients with grade 1 or 2 fibrosis. 18 F-FLT PET showed the same distribution of uptake as BMS in 13 of 14 patients (1 patient did not undergo BMS). In 1 patient, 18 F-FLT PET clearly showed an intense abnormal splenic uptake, whereas spleen uptake was inconclusive with BMS. Conclusion: 18 F-FLT PET appears to be a reliable and convenient technique to assess hematopoietic activity in bone marrow. It yields results close to those observed with BMS. In our study population, 18 F-FLT uptake in the axial skeleton and proximal limbs assessed by SUV max correlated with the grade of fibrosis. Thus, 18 F-FLT PET may be a useful tool to measure the severity of myelofibrosis, and to monitor noninvasively the patients' status during follow-up. Finally, 18 F-FLT PET may be foreseen as an alternative to BMS., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2017
Full Text
View/download PDF

41. Hind limb unloading, a model of spaceflight conditions, leads to decreased B lymphopoiesis similar to aging.

Author

Lescale C, Schenten V, Djeghloul D, Bennabi M, Gaignier F, Vandamme K, Strazielle C, Kuzniak I, Petite H, Dosquet C, Frippiat JP, and Goodhardt M

Subjects
Adrenal Cortex Hormones metabolism, Aging, Animals, Bone Marrow Cells cytology, Bone Remodeling, Cell Differentiation, Cell Lineage, Cytokines metabolism, Hematopoietic Stem Cells cytology, Immunoglobulins metabolism, Interleukin-7 metabolism, Mice, Mice, Inbred C57BL, Models, Animal, PAX5 Transcription Factor metabolism, STAT5 Transcription Factor metabolism, Stem Cells, Time Factors, Trans-Activators metabolism, X-Ray Microtomography, B-Lymphocytes cytology, Hindlimb Suspension physiology, Lymphopoiesis physiology, Space Flight
Abstract

Within the bone marrow, the endosteal niche plays a crucial role in B-cell differentiation. Because spaceflight is associated with osteoporosis, we investigated whether changes in bone microstructure induced by a ground-based model of spaceflight, hind limb unloading (HU), could affect B lymphopoiesis. To this end, we analyzed both bone parameters and the frequency of early hematopoietic precursors and cells of the B lineage after 3, 6, 13, and 21 d of HU. We found that limb disuse leads to a decrease in both bone microstructure and the frequency of B-cell progenitors in the bone marrow. Although multipotent hematopoietic progenitors were not affected by HU, a decrease in B lymphopoiesis was observed as of the common lymphoid progenitor (CLP) stage with a major block at the progenitor B (pro-B) to precursor B (pre-B) cell transition (5- to 10-fold decrease). The modifications in B lymphopoiesis were similar to those observed in aged mice and, as with aging, decreased B-cell generation in HU mice was associated with reduced expression of B-cell transcription factors, early B-cell factor (EBF) and Pax5, and an alteration in STAT5-mediated IL-7 signaling. These findings demonstrate that mechanical unloading of hind limbs results in a decrease in early B-cell differentiation resembling age-related modifications in B lymphopoiesis., (© FASEB.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results